<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00442806</url>
  </required_header>
  <id_info>
    <org_study_id>APOLLO - 01</org_study_id>
    <nct_id>NCT00442806</nct_id>
  </id_info>
  <brief_title>Randomized Clinical Trial of Adipose-Derived Stem Cells in the Treatment of Pts With ST-elevation Myocardial Infarction</brief_title>
  <official_title>A Randomized Clinical Trial of AdiPOse-derived Stem ceLLs in the Treatment of Patients With ST-elevation myOcardial Infarction - The APOLLO Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytori Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytori Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish safety and feasibility of utilizing Adipose-Derived
      Stem and Regenerative Cells (ADRC's) in patients who have suffered a ST-elevation acute
      myocardial infarction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who have coronary artery disease and have suffered a ST-elevation acute myocardial
      infarction will be evaluated for eligibility in this study. Eligible subjects will undergo
      standard treatment after admission to the hospital and will then undergo liposuction under
      local anesthesia, after which ADRC's will be isolated from the lipoaspirate. According to
      randomization subjects will receive either ADRC's or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Determined by Major Adverse Cardiac and Cerebral Events (MACCE)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility - Assessment of cardiac function via functional and imaging studies including MRI, SPECT, and Echocardiography</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Coronary Arteriosclerosis</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is injected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADRC's are injected</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injection of ADRC's</intervention_name>
    <description>ADRC's are injected</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Injection of Placebo</intervention_name>
    <description>Placebo is injected</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Acute myocardial infarction (AMI)

          -  Clinical symptoms consistent with AMI for a minimum of 2 and a maximum of 12 hours
             from onset of symptoms to Percutaneous Coronary Intervention (PCI), and unresponsive
             to nitroglycerin

          -  Successful revascularization of the culprit lesion in the major epicardial vessel

          -  Area of hypo- or akinesia corresponding to the culprit lesion, as determined by left
             ventriculogram at the time of primary PCI

          -  Left ventricular ejection fraction (LVEF) ≥30% and ≤50% by Left Ventricular
             Angiography at the time of successful revascularization.

          -  Ability to undergo liposuction

        Key Exclusion Criteria:

          -  Prior MI, prior known cardiomyopathy, or prior hospital admission for congestive heart
             failure (CHF)

          -  More than 24 hours after acute PCI

          -  Significant valvular disease

          -  More than twelve hours between the onset of first symptoms of AMI and
             revascularization

          -  Hemodynamic instability within 24 hours prior to randomization

          -  Neoplasia

          -  Acute or chronic bacterial or viral infectious disease

          -  Pacemaker, ICD or any other contra-indication for MRI

          -  LVEF &lt;30% or &gt;50% by Left Ventricular Angiography

          -  Moderate or severe COPD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Duckers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus University Medical Centrum, ThoraxCenter</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erasmus University Medical Centrum, Thorax Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2007</study_first_submitted>
  <study_first_submitted_qc>March 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2007</study_first_posted>
  <last_update_submitted>November 25, 2013</last_update_submitted>
  <last_update_submitted_qc>November 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADRC</keyword>
  <keyword>Stem Cells</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>STEMI</keyword>
  <keyword>Heart Disease</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Coronary Disease</keyword>
  <keyword>ST-Elevation</keyword>
  <keyword>AMI</keyword>
  <keyword>Interventional Cardiology</keyword>
  <keyword>Heart Attack</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

